Courtesy Arindam Roy
Nearly every morning, Sarmistha Sen went for a run before her children, Neil, 12, and Ryan, 6, woke up. Like every part of Sarmistha’s routine, running served a purpose in her life. The solitude of running on her neighborhood hike and bike trail with playgrounds on one side and a creek on the other, helped Sarmistha recharge from the demands of her busy schedule. Related Story
As her brother Sumit Sen says, running was her release, which helped her be present, connect fully to others, and embrace her daily purpose.
When she finished her run, Sarmistha would come home, make breakfast for her boys and her husband Arindam Roy, and then start her work as a clinical research manager at the University of Texas Southwestern Medical Center.
Why Alzheimer s Sufferers Seem Lost in Time and Place – Texas Monthly
texasmonthly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasmonthly.com Daily Mail and Mail on Sunday newspapers.
Taysha Gene Therapies picks Durham for 200-job, $75 million expansion
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
by Jim Shamp, NCBiotech writer December 17, 2020 .
RESEARCH TRIANGLE PARK – Dallas-based Taysha Gene Therapies announced plans today to invest $75 million in a gene therapy manufacturing facility in Durham that will employ more than 200 people.
Taysha is joining the fast-growing community of cutting-edge gene- and cell-therapy companies setting up shop in the Research Triangle, where decades of investment and workforce training have created a magnet for the discovery and manufacture of science’s game-changers in fighting some of humankind’s most fearsome maladies.
Taysha logo
The company is developing gene therapies that use benign adeno-associated viruses (AAV) as “vectors,” or carriers, to transport genetic corrections to otherwise defective areas of the body. Taysha is initially targeting genetic diseases of the central nervous system, such as CLN1 disease, also called infantile Batten disease, which causes developmental delays in children, and Rett syndrome, a